Cargando…
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital
The last decade in oncology has witnessed impressive response rates with targeted therapies, largely because of collaborative efforts at understanding tumor biology and careful patient selection based on molecular fingerprinting of the tumor. Consequently, there has been a push toward routine molecu...
Autores principales: | Bardia, Aditya, Iafrate, John A., Sundaresan, Tilak, Younger, Jerry, Nardi, Valentina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016066/ https://www.ncbi.nlm.nih.gov/pubmed/27551012 http://dx.doi.org/10.1634/theoncologist.2016-0240 |
Ejemplares similares
-
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series
por: Brett, Jamie O, et al.
Publicado: (2022) -
4429 Powering precision medicine research with the efficient construction of large diverse cohorts
por: Petukhova, Lynn, et al.
Publicado: (2020) -
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021) -
4199 A pilot randomized controlled trial of precision care for smoking cessation in the Southern Community Cohort Study
por: Senft, Nicole, et al.
Publicado: (2020) -
4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI)
por: Mosley, Scott, et al.
Publicado: (2020)